

## Format for ANSWERING REVIEWERS

May 28, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 10897\_revised.doc).

**Title: Benefits and Risks of Erythrocyte-Stimulating Agents**

**Author:** Daisuke Katagiri, Fumihiko Hinoshita

**Name of Journal:** World Journal of Clinical Urology

**ESPS Manuscript NO:** 10897

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) We amended p5 line 6; rHu Epo to Human Epo

(2) We defined CKD staging in the article as bellows.

1. p6 line 7; CKD 3 - 4 (GFR 15 - 59 ml/min/1.73 m<sup>2</sup>). Thus, CKD 3 - 4 in p8 line13 is not changed.

2. p6 line 10; CKD 5D (GFR < 15 ml/min/1.73 m<sup>2</sup> and on maintainance renal replacement therapy). Thus, CKD 5D in p8 line2 is not changed.

3. p8 line 9; CKD 3 - 5 (GFR < 59 ml/min/1.73 m<sup>2</sup>)

3 References and typesetting were corrected.

Thank you again for publishing our manuscript in the *World Journal of Clinical Urology*.

Sincerely yours,



Daisuke Katagiri, MD, PhD.

7-3-1 Hongo, Bunkyo, Tokyo 113-8655

Tel +81-3-3815-5411 / Fax: +81-3-5800-8806

E-mail: dkatagiri-ky@umin.ac.jp

